Iovance Biotherapeutics' Q3 earnings exceeded expectations with $58.6m in revenue, but shares fell due to high market expectations and competition concerns. Despite challenges, the company shows strong growth potential, particularly with its lead drug Amtagvi, suggesting a 'buy the dip' opportunity for risk-tolerant investors.